Biophytis SA :Biophytis Reports Positive Post-Hoc Analysis Of The Phase 2-3 Cova Clinical Study Strongly Supporting Therapeutic Potential Of Sarconeos (Bio101) In Covid-19.A Reduction In Risk Of Early Death Or Respiratory Failure At Day 28 Of 45% In Intent-To-Treat (Itt) Population And 53% In Per Protocol (Pp) Population.A Reduction In Risk Of Death At Day 90 Of 43% In Itt Population And 70% In Pp Population.Start Of Regulatory Development Of Sarconeos (Bio101) Targeting Conditional And Emergency Use Marketing Authorisations In 2023.